ELABNasdaqPharmaceutical PreparationsFiscal year ends December 31

PMGC Holdings Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$2.83+0.06 (+2.17%)

Close on Oct 19, 2026

Market cap: $13.80M
P/E (TTM): –
Dividend yield: –

SEC filings

40 of PMGC's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Sep 18, 2026	Sep 18, 2026	SEC EDGAR
Current report	8-K	Aug 27, 2026	Sep 2, 2026	SEC EDGAR
Current report	8-K	Aug 21, 2026	Aug 27, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 14, 2026	SEC EDGAR
Current report	8-K	Jul 2, 2026	Jul 9, 2026	SEC EDGAR
Current report	8-K	Jun 30, 2026	Jul 7, 2026	SEC EDGAR
Current report	8-K	Jul 1, 2026	Jul 1, 2026	SEC EDGAR
Current report	8-K	Jun 5, 2026	Jun 8, 2026	SEC EDGAR
Current report	8-K	Jun 1, 2026	Jun 5, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 5, 2026	May 15, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 15, 2026	SEC EDGAR
Current report	8-K	May 11, 2026	May 13, 2026	SEC EDGAR
Current report	8-K	Apr 28, 2026	Apr 28, 2026	SEC EDGAR
Current report	8-K	Apr 23, 2026	Apr 23, 2026	SEC EDGAR
Current report	8-K	Apr 21, 2026	Apr 21, 2026	SEC EDGAR
Current report	8-K	Apr 16, 2026	Apr 17, 2026	SEC EDGAR
Current report	8-K	Apr 9, 2026	Apr 9, 2026	SEC EDGAR
Current report	8-K	Apr 8, 2026	Apr 8, 2026	SEC EDGAR
Current report	8-K	Apr 6, 2026	Apr 6, 2026	SEC EDGAR
Current report	8-K	Apr 2, 2026	Apr 2, 2026	SEC EDGAR
Current report	8-K	Mar 31, 2026	Mar 31, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 30, 2026	SEC EDGAR
Current report	8-K	Mar 24, 2026	Mar 27, 2026	SEC EDGAR
Current report	8-K	Mar 24, 2026	Mar 24, 2026	SEC EDGAR
Current report	8-K	Mar 17, 2026	Mar 23, 2026	SEC EDGAR
Current report	8-K	Mar 4, 2026	Mar 10, 2026	SEC EDGAR
Current report	8-K	Feb 6, 2026	Mar 3, 2026	SEC EDGAR
Current report	8-K	Feb 19, 2026	Feb 19, 2026	SEC EDGAR
Current report	8-K	Feb 11, 2026	Feb 11, 2026	SEC EDGAR
Current report	8-K	Feb 4, 2026	Feb 10, 2026	SEC EDGAR
Current report	8-K	Feb 2, 2026	Feb 6, 2026	SEC EDGAR
Current report	8-K	Jan 13, 2026	Jan 20, 2026	SEC EDGAR
Current report	8-K	Jan 7, 2026	Jan 12, 2026	SEC EDGAR
Current report	8-K	Jan 6, 2026	Jan 6, 2026	SEC EDGAR
Current report	8-K	Dec 17, 2025	Dec 22, 2025	SEC EDGAR
Current report	8-K	Dec 4, 2025	Dec 10, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 14, 2025	SEC EDGAR
Current report	8-K	Oct 30, 2025	Oct 30, 2025	SEC EDGAR
Current report	8-K	Oct 26, 2025	Oct 30, 2025	SEC EDGAR
Proxy statement	DEF 14A	Dec 4, 2025	Oct 27, 2025	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in PMGC's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on Aug 21, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ELAB.

Gross margin31.1% · median 61.1%

Net margin-523.0% · median -114.3%

Company	Revenue	Growth
ENSC	$4.50M	-39.3%
CPHI	$3.91M	-11.0%
PMHS	$3.17M	+7688.8%
BIOE	$2.91M	+416.6%
ELAB	$2.58M	–
PTCHF	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 32
Auditor: HTL International, LLC
SEC CIK: 1840563

Advertisement
300 × 250